$1.18 Billion is the total value of Casdin Capital, LLC's 40 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 38.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $117,409,000 | -28.1% | 805,000 | -19.5% | 9.93% | +35.6% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $58,087,000 | -41.3% | 1,150,000 | -25.8% | 4.91% | +10.6% |
| FATE | Sell | FATE THERAPEUTICS INC | $52,038,000 | -60.5% | 2,100,000 | -38.2% | 4.40% | -25.6% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $48,724,000 | -22.0% | 650,000 | -18.8% | 4.12% | +47.0% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $25,560,000 | -44.3% | 800,000 | -39.6% | 2.16% | +5.0% |
| EXAS | Sell | EXACT SCIENCES CORP | $17,726,000 | -80.9% | 450,000 | -66.2% | 1.50% | -64.1% |
| TWST | Sell | TWIST BIOSCIENCE CORP | $17,480,000 | -59.8% | 500,000 | -43.2% | 1.48% | -24.1% |
| AGIO | Sell | AGIOS PHARMACEUTICALS INC | $17,403,000 | -71.4% | 785,000 | -62.4% | 1.47% | -46.1% |
| Sell | TANGO THERAPEUTICS INC | $15,855,000 | -61.9% | 3,500,000 | -36.2% | 1.34% | -28.1% | |
| BEAM | Sell | BEAM THERAPEUTICS INC | $14,516,000 | -69.1% | 375,000 | -54.2% | 1.23% | -41.7% |
| GH | Sell | GUARDANT HEALTH INC | $10,993,000 | -60.5% | 272,500 | -35.1% | 0.93% | -25.5% |
| Sell | EXSCIENTIA PLCads | $7,230,000 | -29.7% | 663,900 | -7.0% | 0.61% | +32.5% | |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $6,512,000 | -22.7% | 97,000 | -5.4% | 0.55% | +45.8% |
| GLUE | Sell | MONTE ROSA THERAPEUTICS INC | $4,940,000 | -63.3% | 510,882 | -46.8% | 0.42% | -30.8% |
| OMIC | Sell | SINGULAR GENOMICS SYSTEMS IN | $3,307,000 | -63.7% | 865,722 | -40.0% | 0.28% | -31.4% |
| MGTA | Sell | MAGENTA THERAPEUTICS INC | $2,898,000 | -64.0% | 2,415,000 | -12.9% | 0.24% | -32.1% |
| NVTA | Sell | INVITAE CORP | $2,534,000 | -97.4% | 1,038,388 | -91.5% | 0.21% | -95.1% |
| Sell | SCIENCE 37 HOLDINGS INC | $452,000 | -95.3% | 225,000 | -87.5% | 0.04% | -91.2% | |
| KRON | Sell | KRONOS BIO INC | $451,000 | -89.3% | 123,839 | -78.8% | 0.04% | -79.9% |
| DBTX | Exit | DECIBEL THERAPEUTICS INC | $0 | – | -330,000 | -100.0% | -0.04% | – |
| RXRX | Exit | RECURSION PHARMACEUTICALS INcl a | $0 | – | -548,156 | -100.0% | -0.18% | – |
| CDXS | Exit | CODEXIS INC | $0 | – | -300,000 | -100.0% | -0.28% | – |
| ZLAB | Exit | ZAI LAB LTDadr | $0 | – | -150,000 | -100.0% | -0.30% | – |
| GBIO | Exit | GENERATION BIO CO | $0 | – | -1,324,275 | -100.0% | -0.44% | – |
| SEER | Exit | SEER INC | $0 | – | -800,000 | -100.0% | -0.55% | – |
| ADPT | Exit | ADAPTIVE BIOTECHNOLOGIES COR | $0 | – | -1,000,000 | -100.0% | -0.62% | – |
| Exit | GINKGO BIOWORKS HOLDINGS INC | $0 | – | -4,202,808 | -100.0% | -0.76% | – | |
| Exit | DERMTECH INC | $0 | – | -1,745,000 | -100.0% | -1.15% | – | |
| BGNE | Exit | BEIGENE LTDsponsored adr | $0 | – | -150,000 | -100.0% | -1.27% | – |
| CDNA | Exit | CAREDX INC | $0 | – | -1,153,335 | -100.0% | -1.91% | – |
| PACB | Exit | PACIFIC BIOSCIENCES CALIF IN | $0 | – | -7,990,652 | -100.0% | -3.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.